Expanding the Use of Inhaled Vasodilators in Managing Right Ventricular Dysfunction in the Emergency and Critical Care Setting: Should We Broaden Our Vision?
Restricted accessEditorialFirst published online July, 2019
Expanding the Use of Inhaled Vasodilators in Managing Right Ventricular Dysfunction in the Emergency and Critical Care Setting: Should We Broaden Our Vision?
Pepke-ZabaJ, HigenbottamTW, Dinh-XuanAT, StoneD, WallworkJ. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet, 1991; 338(8776):1173–1174.
2.
OlschewskiH, GhofraniHA, WalmrathD, SchermulyR, Temmesfeld-WollbruckB, GrimmingerF, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med, 1999; 160(2):600–607.
3.
WangL, JinYZ, ZhaoQH, JiangR, WuWH, GongSG, et al. Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension. Int J Chron Obstruct Pulmon Dis, 2017; 12:3353–3360.
4.
RobertsJD, PolanerDM, LangP, ZapolWM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet, 1992; 340(8823):818–819.
PappertD, BuschT, GerlachH, LewandowskiK, RadermacherP, RossaintR. Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome. Anesthesiology, 1995; 82(6):1507–1511.
7.
RossaintR, SlamaK, SteudelW, GerlachH, PappertD, VeitS, et al. Effects of inhaled nitric oxide on right ventricular function in severe acute respiratory distress syndrome. Intensive Care Med, 1995; 21(3):197–203.
8.
OlschewskiH, WalmrathD, SchermulyR, GhofraniA, GrimmingerF, SeegerW. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med, 1996; 124(9):820–824.
9.
EnomotoTM, TreggiariMM, MerkelMJ. Inhaled iloprost versus epoprostenol in heart transplant recipients. Respir Care, 2019; 64(7):743–751.
10.
SablotzkiA, CzeslickE, SchubertS, FriedrichI, MuhlingJ, DehneMG, et al. Iloprost improves hemodynamics in patients with severe chronic cardiac failure and secondary pulmonary hypertension. Can J Anaesth, 2002; 49(10):1076–1080.
11.
BautinAE, IakovlevAS, TashkhanovDM, DatsenkoSV, MarichevAO, PopovMA, et al. [Specifics of inhaled iloprost pharmacodynamics in patients with severe left ventricular systolic dysfunction]. Anesteziol Reanimatol, 2015; 60(2):4–7.
12.
RochwergB, BrochardL, ElliottMW, HessD, HillNS, NavaS, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J, 2017; 50(2):1602426.
13.
NishimuraM. High-flow nasal cannula oxygen therapy in adults: physiological benefits, indication, clinical benefits, and adverse effects. Respir Care, 2016; 61(4):529–541.
14.
ZochiosV, ParharK, TunnicliffeW, RoscoeA, GaoF. The right ventricle in ARDS. Chest, 2017; 152(1):181–193.
15.
ZapolWM, SniderMT. Pulmonary hypertension in severe acute respiratory failure. N Engl J Med, 1977; 296(9):476–480.
16.
MessikaJ, Ben AhmedK, GaudryS, Miguel-MontanesR, RafatC, SztrymfB, et al. Use of high-flow nasal cannula oxygen therapy in subjects with ARDS: a 1-year observational study. Respir Care, 2015; 60(2):162–169.
17.
BellaniG, LaffeyJG, PhamT, MadottoF, FanE, BrochardL, et al. Noninvasive ventilation of patients with acute respiratory distress syndrome. Insights from the LUNG SAFE Study. Am J Respir Crit Care Med, 2017; 195(1):67–77.
